Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer

Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.

intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.

Targeted drugs for non-small cell lung cancer:

EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .

endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.

Leptomeningeal Metastasis Overall survival defined as time from LM diagnosis to death due to any cause or last follow-up

From the start of treatment until central nervous system metastase progression or death due to any cause

From date of first dose up to assessed from April 2020 to April 2023 (In accordance with the standard of CTCAE)

ORR, proportion of patients with a best overall response of complete response or partial response (CR+PR)

In accordance with the standard of Response Assessment in Neuro-Oncology(RANO) Neurological Assessment group.The maximum value is 29 and the minimum value is 0.The higher scores mean a worse outcome.